The U.S. House approved the bipartisan INVEST Act to ease regulatory barriers and expand capital access for small innovative firms, a move endorsed by the Biotechnology Innovation Organization and other industry groups. The legislation bundles measures to incentivize early‑stage investment and tax changes intended to improve financing opportunities for startups and small biotechs. BIO and industry advocates argued the bill will help bridge the funding gap that hinders translation of early science, while supporters said it would strengthen U.S. competitiveness in life‑science innovation.